Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.57 |
| ▸ | AHR | P35869 | 3/20 | 0.56 |
| ▸ | CMA1 | P23946 | 2/20 | 0.56 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 2/20 | 0.52 |
| ▸ | TDP2 | O95551 | 6/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260027 | 0.87 | AHR (0.61) | CRBNAHRCMA1EIF2AK2TDP2 | |
| SCHEMBL30648196 | 0.87 | AHR (0.61) | CRBNAHRCMA1EIF2AK2TDP2 | |
| SCHEMBL1897593 | 0.86 | PDE3B (0.68) | AHRPGRTDP2PDE3BPDE3A | |
| SCHEMBL7717893 | 0.85 | AHR (0.59) | CRBNAHRCMA1EIF2AK2TDP2 | |
| SCHEMBL4408889 | 0.84 | TDP2 (0.65) | CRBNAHRCMA1EIF2AK2PGR | |
| SCHEMBL22643434 | 0.82 | CRBN (0.55) | CRBNAHRCMA1EIF2AK2PGR | |
| Methylamine SCHEMBL28014455 | 0.82 | AHR (0.56) | CRBNAHRCMA1EIF2AK2PGR | |
| SCHEMBL13529011 | 0.82 | CRBN (0.61) | CRBNAHRCMA1EIF2AK2PGR | |
| SCHEMBL4014709 | 0.82 | TDP2 (0.66) | CRBNAHRCMA1EIF2AK2PGR | |
| SCHEMBL23143582 | 0.81 | CRBN (0.50) | CRBNAHRCMA1EIF2AK2TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071332-B2 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1259514-B9 | 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN INC (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1259514-B1 | 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050032871-A1 | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2005-02-10 | — | — | US | disclosed |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | disclosed |
| US-6706709-B2 | TREATING, FOR EXAMPLE, PROLIFERATIVE DISORDERS INCLUDING CANCER | SUGEN, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1259514-A2 | 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6465507-B2 | ANTITUMOR AGENTS | SUGEN, INC. | 2002-10-15 | — | — | US | disclosed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | disclosed |
| US-20020042427-A1 | 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors | SUGEN, INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001064681-A2 | 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | CRBN 1968/4885AHR 2963/4885CMA1 4512/4885 |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | CRBN 1979/4885AHR 2554/4885CMA1 1226/4885 |
| US-20050032871-A1 | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors | MAP3K20, CDK20, STK10 | CRBN 2064/4885AHR 2417/4885CMA1 1692/4885 |
| US-20020042427-A1 | 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors | MAP3K20, MAP3K6, MAP3K3 | CRBN 1717/4885AHR 2465/4885CMA1 3642/4885 |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | CRBN 1979/4885AHR 2554/4885CMA1 1226/4885 |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | CRBN 2039/4885AHR 810/4885CMA1 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.